Market Place
Sourcing Support
All News #Library
Biotech
Bicara Therapeutics to Report Q1 2026 Results on May 11
04 May 2026 //
GLOBENEWSWIRE
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Rules
03 Apr 2026 //
GLOBENEWSWIRE
Bicara Therapeutics Reports Q4 2025 Results and Business Update
30 Mar 2026 //
GLOBENEWSWIRE
Bicara Therapeutics Completes Oversubscribed Public Offering
26 Feb 2026 //
GLOBENEWSWIRE
Bicara Therapeutics Joins Upcoming Investor Conferences
23 Feb 2026 //
GLOBENEWSWIRE
Bicara Therapeutics Awards Equity Grants Under Nasdaq Rule
05 Feb 2026 //
GLOBENEWSWIRE
Bicara Bio Reveals Phase 3 Dose, 2026 Outlook
12 Jan 2026 //
GLOBENEWSWIRE
Bicara Therapeutics at 2026 J.P. Morgan Healthcare Conference
15 Dec 2025 //
GLOBENEWSWIRE
Bicara Phase 1b Data Supports Ficerafusp Dose for Pivotal Study
06 Dec 2025 //
GLOBENEWSWIRE
Bicara Therapeutics Publishes Phase 1b Data On Ficerafusp Alfa
01 Dec 2025 //
GLOBENEWSWIRE
Bicara Pharma`s Ficerafusp Alfa Earns Breakthrough Designation
13 Oct 2025 //
GLOBENEWSWIRE
One Of The Lucky Few`: Bicara Ceo On Last Year`S $326M Ipo
14 Apr 2025 //
FIERCE BIOTECH
Bicara Begins Ph2/3 Ficerafusp Alfa Trial In Head, Neck Cancer
11 Feb 2025 //
GLOBENEWSWIRE
Upstream Bio, two other US biotech startups price IPOs
11 Oct 2024 //
REUTERS
Bicara Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101)
27 Jun 2024 //
BUSINESSWIRE
Bicara’s BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab
05 Jun 2023 //
BUSINESSWIRE
Data show Bicara’s bispecific helps shrink head when combined with Keytruda
05 Jun 2023 //
ENDPTS
Bicara Therapeutics to Present at 2023 Jefferies Global Healthcare Conference
01 Jun 2023 //
BUSINESSWIRE
Bicara Therapeutics to Present Preclinical Data from BCA101, at AACR
04 Apr 2023 //
BUSINESSWIRE
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing
06 Mar 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.